Results 21 to 30 of about 30,955 (215)

Optical Coherence Tomography-Angiography of Different Choroidal Neovascularization Subtypes in Wet Age-related Macular Degeneration

open access: yesFolia Medica, 2019
Age-related macular degeneration is a leading cause of irreversible vision loss in individuals over 55 years of age worldwide. Conventionally, it is divided into two subtypes – dry (non-neovascular) and wet (neovascular) form.
Stavrev Vladimir N.   +2 more
doaj   +1 more source

New Frontiers in Retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium

open access: yesInternational Journal of Retina and Vitreous, 2020
We summarize the most important findings presented at the 2020 angiogenesis, exudation and degeneration symposium in five topic areas: (1) epidemiology of retinal vascular disease and macular degeneration; (2) dry AMD and geographic atrophy; (3 ...
Carmen A. Puliafito, Charles C. Wykoff
doaj   +1 more source

Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article [PDF]

open access: yes, 2017
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD).
Elena Gusson   +8 more
core   +1 more source

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy

open access: yesRevista Brasileira de Oftalmologia, 2013
The authors relate a predominantly hemorrhagic choroidal neovascular lesion from neovascular. Age-related macular degeneration patient case treated with intravitreal ranibizumab therapy.
Miguel Hage Amaro, Aaron Brock Holler
doaj   +1 more source

Radiotherapy for neovascular age-related macular degeneration [PDF]

open access: yesCochrane Database of Systematic Reviews, 2010
Radiotherapy has been proposed as a treatment to prevent new vessel growth in people with neovascular age-related macular degeneration (AMD).The aim of this review was to examine the effects of radiotherapy on neovascular AMD.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group ...
Evans, JR, Sivagnanavel, V, Chong, V
openaire   +4 more sources

Optical Coherence Tomographic Angiography Imaging in Age-Related Macular Degeneration. [PDF]

open access: yes, 2017
Optical coherence tomographic angiography (OCTA) is emerging as a rapid, noninvasive imaging modality that can provide detailed structural and flow information on retinal and choroidal vasculature.
Desai, Ria   +5 more
core   +3 more sources

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab

open access: yesInternational Journal of Ophthalmology, 2017
AIM: To report the change in visual acuity and central macular thickness (CMT) following treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration (nAMD) with suboptimum response to ranibizumab ...
Rachel Hui Fen Lim   +2 more
doaj   +1 more source

Plasma lipoprotein subfraction concentrations are associated with lipid metabolism and age-related macular degeneration [PDF]

open access: yes, 2017
10.1194/jlr.M073684Journal of Lipid Research5891785 ...
Apte, Rajendra S.   +10 more
core   +2 more sources

FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice

open access: yesCell Reports, 2017
Pathological neovascularization, a leading cause of blindness, is seen in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
Zhongjie Fu   +12 more
doaj   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

open access: yes, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T.   +9 more
core   +2 more sources

Home - About - Disclaimer - Privacy